O
Oskar Hansson
Researcher at Lund University
Publications - 659
Citations - 38798
Oskar Hansson is an academic researcher from Lund University. The author has contributed to research in topics: Medicine & Dementia. The author has an hindex of 88, co-authored 496 publications receiving 26159 citations. Previous affiliations of Oskar Hansson include University College London & King's College London.
Papers
More filters
Journal ArticleDOI
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Oskar Hansson,Oskar Hansson,Henrik Zetterberg,Peder Buchhave,Peder Buchhave,Elisabet Londos,Elisabet Londos,Kaj Blennow,Lennart Minthon,Lennart Minthon +9 more
TL;DR: The association between pathological CSF and progression to Alzheimer's disease was much stronger than, and independent of, established risk factors including age, sex, education, APOE genotype, and plasma homocysteine.
Journal ArticleDOI
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson,Henrik Zetterberg,Oskar Hansson,Niels Andreasen,Lucilla Parnetti,Michael Jonsson,Sanna-Kaisa Herukka,Wiesje M. van der Flier,Marinus A. Blankenstein,Michael Ewers,Kenneth Rich,Elmar Kaiser,Marcel M. Verbeek,Magda Tsolaki,Ezra Mulugeta,Erik Rosén,Dag Aarsland,Pieter Jelle Visser,Johannes Schröder,Jan Marcusson,Mony J. de Leon,Harald Hampel,Philip Scheltens,Tuula Pirttilä,Anders Wallin,Maria Eriksdotter Jönhagen,Lennart Minthon,Bengt Winblad,Kaj Blennow +28 more
TL;DR: This multicenter study found that CSF Abeta42, T-t Tau, and P-tau identify incipient AD with good accuracy, but less accurately than reported from single-center studies.
Journal ArticleDOI
Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease.
Melinda M Zeron,Oskar Hansson,Nansheng Chen,Cheryl L. Wellington,Blair R. Leavitt,Patrik Brundin,Michael R. Hayden,Lynn A. Raymond +7 more
TL;DR: The data support a role for NR2B-subtype NMDAR activation as a trigger for selective neuronal degeneration in HD, and increased NMDA-evoked current amplitude and caspase-3 activity were observed in transgenic striatal neurons.
Journal ArticleDOI
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
TL;DR: Almost 90% of patients with mild cognitive impairment and pathologic CSF biomarker levels at baseline develop AD within 9 to 10 years, providing direct support in humans for the hypothesis that altered Aβ metabolism precedes tau-related pathology and neuronal degeneration.
Journal ArticleDOI
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Shorena Janelidze,Niklas Mattsson,Sebastian Palmqvist,Ruben Smith,Thomas G. Beach,Geidy E. Serrano,Xiyun Chai,Nicholas K. Proctor,Udo Eichenlaub,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Eric M. Reiman,Erik Stomrud,Jeffrey L. Dage,Oskar Hansson +15 more
TL;DR: Plasma P-tau18 level increased with progression of Alzheimer’s disease (AD) and differentiated AD dementia from other neurodegenerative diseases, supporting its further development as a blood-based biomarker for AD.